Sectors: Healthcare, Pharma & Life Sciences

Banking & Finance

Engimmune Therapeutics raises CHF 15.5m in seed financing round 

Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch.  Engimmune Therapeutics is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment.  Proceeds from the financing will be used to develop novel T-cell […]

Deal & transactions

Astorg signs binding agreement with ICIG to acquire CordenPharma

Private equity firm Astrog has entered into a binding agreement with privately owned industrial group International Chemical Investors Group (“ICIG”) whereby Astorg will acquire CordenPharma, a global pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with highly differentiated capabilities in Active Pharmaceutical Ingredients, Excipients, and Drug Products, from ICIG. As part of the transaction, the founders […]

Banking & Finance

CDR-Life raises USD 76 million in its Series A Financing

CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital Management, with participation from Omega Funds. Homburger advised CDR-Life in the transaction. The Homburger team was led by partner […]

Capital Markets News

Advestra: GBL acquires a majority stake in Sanoptis

Groupe Bruxelles Lam­bert (GBL) acquires a major­ity stake in San­optis, a net­work of oph­thal­mo­logy clin­ics across Ger­many and Switzer­land, from the private equity Telemos Cap­it­al. GBL is com­mit­ting up to EUR 750 mil­lion in equity for this trans­ac­tion with the aim to accelerate the company’s growth in partnership with its management and doctors. In this sense, as part of the transaction, the […]

Deal & transactions

Brust-Zentrum Zurich enters into a strategic partnership with Affidea

Bär & Karrer advised on the sale of Brust-Zentrum Zurich, a Swiss medical center specialised in the diagnosis and professional treatment of the breast. The owners of Brust-Zentrum Zurich have entered a strategic alliance with Affidea, a european provider of advanced diagnostic imaging, cancer therapies and outpatient services. With this partnership, Affidea Switzerland expands in […]

Deal & transactions

MLL advised DentaCore on the acquisition of Cera-Tech  

DentaCore, a privately held corporation specialising in acquisitions, investments and consolidation in the fragmented dental medicine sector, has acquired Cera-Tech, an innovative dental manufacturer.  Headquartered in Switzerland, DentaCore focuses on the integration of outstanding practices, clinics and laboratories. The consistent realization of synergy effects and process optimisation leads to improved services and lower costs for […]

Deal & transactions

MoonLake Immunotherapeutics closes combination with Helix Acquisition

Kellerhals Carrard acted as Swiss legal advisor to MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, in the closing of its previously announced business combination with Helix Acquisition Corp. (“Helix”), a publicly traded special purpose acquisition company.   The business combination was unanimously approved by Helix’s board of directors and was approved […]